PRIMARY STUDY

Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

Key Findings:  Data suggests a therapeutic potential (anti-dyskinesia) of Δ9-THCV. More specifically, THCV was able to delay the occurrence and to attenuate the magnitude of dyskinesia in an animal model of PD.

Type of Study:  Animal Study

Study Result:  Positive


Cannabinoids Studied:  Tetrahydrocannabivarin (THCV)

Phytocannabinoid Source:  Unspecified

Form of Administration:  Injection

Dosage: THCV was administered i.p. at 2 mg/kg for two weeks.


Study Location(s):  Spain

Year of Pub:  2020


Link to study